Kodu・Aktsiate loetelu・Krystal Biotech Inc

Krystal Biotech Inc

Suletud

SektorTervishoid

324.45 0.83

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

319.48

Max

326.37

Põhinäitajad
By Trading Economics
Sissetulek	-1.2M 55M
Müük	2.9M 119M
P/E Sektori keskmine	45.697 68.51
Aktsiakasum	1.79
Kasumimarginaal	45.938
Töötajad	295
EBITDA	2.9M 66M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.95% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	2. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 9.3B
Eelmine avamishind	323.62
Eelmine sulgemishind	324.45

Krystal Biotech Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2026, 19:26 UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

6. aug 2026, 19:26 UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

5. aug 2026, 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4. aug 2026, 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3. aug 2026, 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31. juuli 2026, 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30. juuli 2026, 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29. juuli 2026, 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28. juuli 2026, 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27. juuli 2026, 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24. juuli 2026, 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23. juuli 2026, 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22. juuli 2026, 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21. juuli 2026, 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20. juuli 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Võrdlus sarnastega

Hinnamuutus

Krystal Biotech Inc Prognoos

Hinnasiht

By TipRanks

24.95% tõus

12 kuu keskmine prognoos

Keskmine 403.2 USD 24.95%

Kõrge 474 USD

Madal 361 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Krystal Biotech Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Krystal Biotech Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.